On the public citation graph
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα
0 signed · 251 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/(sici)1521-4141(199812)28:12<4130::aid-immu4130>3.0.co;2-wopenalex-snapshot
The combined inactivation of tumor necrosis factor and interleukin-6 prevents induction of the major acute phase proteins by endotoxin
inferredcites →https://doi.org/10.1002/1529-0131(200001)43:1<76::aid-anr10>3.0.co;2-iopenalex-snapshot
Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus
inferredcites →https://doi.org/10.1002/1529-0131(200010)43:10<2307::aid-anr19>3.0.co;2-jopenalex-snapshot
Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus
inferredcites →https://doi.org/10.1002/1529-0131(200011)43:11<2383::aid-anr2>3.0.co;2-dopenalex-snapshot
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials
inferredcites →https://doi.org/10.1002/art.10876openalex-snapshot
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy
inferredcites →https://doi.org/10.1002/art.11098openalex-snapshot
Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue
inferredcites →https://doi.org/10.1002/art.1780310302openalex-snapshot
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
inferredcites →https://doi.org/10.1007/s002960050058openalex-snapshot
Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms
inferredcites →https://doi.org/10.1007/s10067-002-0654-5openalex-snapshot
Anti-TNF-?-induced systemic lupus syndrome
inferredcites →https://doi.org/10.1016/s0016-5085(03)00701-7openalex-snapshot
Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study
inferredcites →https://doi.org/10.1016/s0016-5085(99)70224-6openalex-snapshot
Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
inferredcites →https://doi.org/10.1016/s0022-3468(00)90238-0openalex-snapshot
Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in crohn's ileocolitis
inferredcites →https://doi.org/10.1016/s0065-2776(08)60891-3openalex-snapshot
Anti-Tumor Necrosis Factor-α Therapy of Rheumatoid Arthritis
inferredcites →https://doi.org/10.1016/s0140-6736(02)07714-0openalex-snapshot
Drug-induced systemic lupus erythematosus associated with etanercept therapy
inferredcites →https://doi.org/10.1016/s0140-6736(99)05246-0openalex-snapshot
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
inferredcites →https://doi.org/10.1016/s1470-0328(02)01048-0openalex-snapshot
Inter-assay variation in antiphospholipid antibody testing
inferredcites →https://doi.org/10.1038/377348a0openalex-snapshot
Induction of apoptosis in mature T cells by tumour necrosis factor
inferredcites →https://doi.org/10.1038/9450openalex-snapshot
SAP-less chromatin triggers systemic lupus erythematosus
inferredcites →https://doi.org/10.1038/ng0598-56openalex-snapshot
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
inferredcites →https://doi.org/10.1056/nejm200011303432202openalex-snapshot
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
inferredcites →https://doi.org/10.1073/pnas.1432897100openalex-snapshot
TNF-αneutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis
inferredcites →https://doi.org/10.1073/pnas.93.24.13973openalex-snapshot
The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex
inferredcites →https://doi.org/10.1093/rheumatology/41.10.1109openalex-snapshot
Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial
inferredcites →https://doi.org/10.1093/rheumatology/keh029openalex-snapshot
Comparison of different kits in the detection of autoantibodies to cardiolipin and beta2glycoprotein 1
inferredcites →https://doi.org/10.1097/00006416-199003000-00011openalex-snapshot
Revised Criteria for the Classification of Rheumatoid Arthritis
inferredcites →https://doi.org/10.1111/j.1365-2796.2003.01298.xopenalex-snapshot
Accumulation of plasma nucleosomes upon treatment with anti‐tumour necrosis factor‐α antibodies
inferredcites →https://doi.org/10.1146/annurev.immunol.17.1.221openalex-snapshot
MATURE T LYMPHOCYTE APOPTOSIS—Immune Regulation in a Dynamic and Unpredictable Antigenic Environment
inferredcites →https://doi.org/10.1186/ar1173openalex-snapshot
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
inferredcites →https://doi.org/10.1191/0961203302lu306rropenalex-snapshot
Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production
inferredcites →https://doi.org/10.4049/jimmunol.159.12.6276openalex-snapshot
A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease
inferredcites →https://doi.org/10.4049/jimmunol.165.5.2738openalex-snapshot
TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells
inferredcites →https://doi.org/10.4049/jimmunol.167.12.6821openalex-snapshot
In Vivo Neutralization of TNF-α Promotes Humoral Autoimmunity by Preventing the Induction of CTL
inferredcites →https://doi.org/10.7326/0003-4819-130-6-199903160-00004openalex-snapshot
Etanercept Therapy in Rheumatoid Arthritis
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4852286openalex-extracted
Tumor Necrosis Factor-Alpha Inhibitors-Induced Systemic Lupus Erythematosus: A Real-World Pharmacovigilance Study Based on the Faers Database
inferred← citeshttps://doi.org/10.1001/archdermatol.2010.142openalex-snapshot
Tumor Necrosis Factor Inhibitor–Associated Dermatomyositis
inferred← citeshttps://doi.org/10.1002/art.21190openalex-snapshot
Infliximab, but not etanercept, induces IgM anti–double‐stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis
inferred← citeshttps://doi.org/10.1002/art.21702openalex-snapshot
Infliximab‐related lupus and associated valvulitis: A case report and review of the literature
inferred← citeshttps://doi.org/10.1002/ddr.20471openalex-snapshot
Anti‐tumor necrosis factor‐α therapies for immune‐mediated and inflammatory skin diseases
inferred← citeshttps://doi.org/10.1002/ibd.21362openalex-snapshot
Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease
inferred← citeshttps://doi.org/10.1002/mus.21051openalex-snapshot
Lewis–Sumner syndrome associated with infliximab therapy in rheumatoid arthritis
inferred← citeshttps://doi.org/10.1007/978-1-4471-4432-8_14openalex-snapshot
Infliximab and Golimumab
inferred← citeshttps://doi.org/10.1007/978-2-8178-0124-7_3openalex-snapshot
Les anti-TNF dans la polyarthrite rhumatoïde
inferred← citeshttps://doi.org/10.1007/978-3-030-54859-9_14openalex-snapshot
Infliximab, Golimumab, and Certolizumab Pegol
inferred← citeshttps://doi.org/10.1007/978-3-319-18446-3_11openalex-snapshot
Iatrogenic Disease and Drug Induced Toxicities Related to Anti-Inflammatory and Immunomodulatory Agents
inferred← citeshttps://doi.org/10.1007/978-3-319-24535-5_6openalex-snapshot
Joint Involvement in Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1007/978-3-319-68790-2_8openalex-snapshot
Skin Diseases Associated with Biologic Therapies
inferred← citeshttps://doi.org/10.1007/978-981-96-7810-5_57openalex-snapshot
The Interpretation of Serological Tests in Interstitial Lung Disease Associated with Collagen-Vascular Diseases
inferred← citeshttps://doi.org/10.1007/s00296-007-0379-5openalex-snapshot
Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis
inferred← citeshttps://doi.org/10.1007/s00393-021-00983-8openalex-snapshot
Anti-TNF-α-induced lupus syndrome
inferred← citeshttps://doi.org/10.1007/s00403-008-0895-5openalex-snapshot
Drug-induced lupus erythematosus
inferred← citeshttps://doi.org/10.1007/s00417-011-1908-1openalex-snapshot
Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet’s disease with infliximab
inferred← citeshttps://doi.org/10.1007/s10067-007-0712-0openalex-snapshot
C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab
inferred← citeshttps://doi.org/10.1007/s10067-007-0728-5openalex-snapshot
Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFα blocking agents in rheumatoid arthritis
inferred← citeshttps://doi.org/10.1007/s10067-015-3140-6openalex-snapshot
Infliximab-induced autoantibodies: a multicenter study
inferred← citeshttps://doi.org/10.1007/s10165-007-0006-zopenalex-snapshot
Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome
inferred← citeshttps://doi.org/10.1007/s10165-011-0419-6openalex-snapshot
The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab
inferred← citeshttps://doi.org/10.1007/s10620-015-3699-4openalex-snapshot
Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease
inferred← citeshttps://doi.org/10.1007/s10620-021-07378-4openalex-snapshot
Advancing Biologic Therapy for Refractory Autoimmune Hepatitis
inferred← citeshttps://doi.org/10.1007/s10875-008-9214-3openalex-snapshot
Impact of Three Anti-TNFα Biologics on Existing and Emergent Autoimmunity in Rheumatoid Arthritis and Spondylarthropathy Patients
inferred← citeshttps://doi.org/10.1007/s11239-017-1571-4openalex-snapshot
Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha
inferred← citeshttps://doi.org/10.1007/s11910-015-0600-yopenalex-snapshot
Prevention of Stroke in Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1007/s11926-004-0021-4openalex-snapshot
Dyslipoproteinemia and premature atherosclerosis in pediatric systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1007/s11926-015-0500-9openalex-snapshot
Antinuclear Antibody (ANA) Testing in Patients Treated With Biological DMARDs: Is It Useful?
inferred← citeshttps://doi.org/10.1007/s12020-015-0551-8openalex-snapshot
Thyroid-specific changes following treatment with biological therapies in patients with rheumatic diseases
inferred← citeshttps://doi.org/10.1007/s12026-013-8410-2openalex-snapshot
Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab
inferred← citeshttps://doi.org/10.1007/s12026-018-8992-9openalex-snapshot
Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests
inferred← citeshttps://doi.org/10.1007/s12072-010-9218-yopenalex-snapshot
Hemophagocytic syndrome occurring in an adult liver transplant recipient having Still’s disease
inferred← citeshttps://doi.org/10.1007/s40259-013-0033-6openalex-snapshot
Adalimumab: A Review of Its Use in the Treatment of Patients with Ulcerative Colitis
inferred← citeshttps://doi.org/10.1007/s40266-023-01079-5openalex-snapshot
Cutaneous Lupus Erythematosus: Review and Considerations for Older Populations
inferred← citeshttps://doi.org/10.1016/b978-0-08-046884-6.00629-1openalex-snapshot
Immunotoxicology of Biopharmaceutics
inferred← citeshttps://doi.org/10.1016/b978-0-08-100601-6.02008-1openalex-snapshot
Immunotoxicology of Biopharmaceutics
inferred← citeshttps://doi.org/10.1016/b978-0-12-374994-9.10033-6openalex-snapshot
Drug-Induced Disease
inferred← citeshttps://doi.org/10.1016/b978-0-12-801238-3.02008-0openalex-snapshot
Immunotoxicology of Biopharmaceutics☆
inferred← citeshttps://doi.org/10.1016/b978-0-323-06551-1.00032-4openalex-snapshot
Skin in rheumatic disease
inferred← citeshttps://doi.org/10.1016/b978-0-323-95488-4.50043-6openalex-snapshot
Immunotoxicology of Biopharmaceutics
inferred← citeshttps://doi.org/10.1016/b978-032305475-1.50046-xopenalex-snapshot
Treatment of Rheumatoid Arthritis: Tumor Necrosis Factor Inhibitors
inferred← citeshttps://doi.org/10.1016/b978-1-4377-0974-2.00051-8openalex-snapshot
Clinical and Laboratory Evaluation of Systemic Rheumatic Diseases
inferred← citeshttps://doi.org/10.1016/b978-84-9022-857-9.50065-8openalex-snapshot
10.1016/b978-84-9022-857-9.50065-8
inferred← citeshttps://doi.org/10.1016/j.ard.2025.08.003openalex-snapshot
Identification of a novel transcriptome signature for predicting the response to anti-TNF-α treatment in patients with rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/j.autrev.2007.03.003openalex-snapshot
Biological and clinical effects of anti-TNFα treatment
inferred← citeshttps://doi.org/10.1016/j.autrev.2008.06.005openalex-snapshot
Anti-chromatin (anti-nucleosome) antibodies: Diagnostic and clinical value
inferred← citeshttps://doi.org/10.1016/j.autrev.2010.07.005openalex-snapshot
Drug-induced lupus: An update
inferred← citeshttps://doi.org/10.1016/j.autrev.2015.04.003openalex-snapshot
The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/j.autrev.2023.103332openalex-snapshot
Tumor necrosis factor-α inhibitor-related autoimmune disorders
inferred← citeshttps://doi.org/10.1016/j.berh.2006.06.002openalex-snapshot
Problems encountered during anti-tumour necrosis factor therapy
inferred← citeshttps://doi.org/10.1016/j.berh.2008.09.008openalex-snapshot
Autoimmune diseases induced by TNF-targeted therapies
inferred← citeshttps://doi.org/10.1016/j.berh.2011.11.003openalex-snapshot
Immune modulation of rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/j.bios.2020.112233openalex-snapshot
Fast and sensitive diagnosis of autoimmune disorders through amperometric biosensing of serum anti-dsDNA autoantibodies
inferred← citeshttps://doi.org/10.1016/j.clim.2007.08.012openalex-snapshot
TNFα blockade in human diseases: An overview of efficacy and safety
inferred← citeshttps://doi.org/10.1016/j.clim.2011.01.012openalex-snapshot
Treatment with TNFα blockers induces phenotypical and functional aberrations in peripheral B cells
inferred← citeshttps://doi.org/10.1016/j.clinre.2011.04.017openalex-snapshot
A lupus-like syndrome induced by infliximab treatment
inferred← citeshttps://doi.org/10.1016/j.clinthera.2006.11.020openalex-snapshot
Role of abatacept in the management of rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/j.crohns.2012.06.016openalex-snapshot
Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease—what is the role of anti-TNF antibody?
inferred← citeshttps://doi.org/10.1016/j.cyto.2008.01.007openalex-snapshot
The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment
inferred← citeshttps://doi.org/10.1016/j.jaad.2007.08.030openalex-snapshot
From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis
inferred← citeshttps://doi.org/10.1016/j.jaad.2008.10.060openalex-snapshot
Cutaneous side effects of anti–tumor necrosis factor biologic therapy: A clinical review
inferred← citeshttps://doi.org/10.1016/j.jaad.2011.06.008openalex-snapshot
The role of antinuclear autoantibodies in patients with psoriasis treated with anti–tumor necrosis factor-alpha agents: A retrospective long-term study
inferred← citeshttps://doi.org/10.1016/j.jaad.2021.01.087openalex-snapshot
Development of dermatomyositis in patients on biologic therapy: A systematic review
inferred← citeshttps://doi.org/10.1016/j.jaut.2011.08.002openalex-snapshot
Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases
inferred← citeshttps://doi.org/10.1016/j.jaut.2014.01.027openalex-snapshot
Diagnosis and classification of rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/j.jbspin.2008.09.010openalex-snapshot
Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/j.jbspin.2008.12.008openalex-snapshot
Anti-TNFalpha blockers, autoantibodies and autoimmune diseases
inferred← citeshttps://doi.org/10.1016/j.jbspin.2015.04.020openalex-snapshot
The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study
inferred← citeshttps://doi.org/10.1016/j.medcli.2009.04.035openalex-snapshot
Lupus inducido por fármacos
inferred← citeshttps://doi.org/10.1016/j.revmed.2005.11.002openalex-snapshot
Les anti-TNF : une contre-indication ou un traitement prometteur du lupus ?
inferred← citeshttps://doi.org/10.1016/j.rhum.2008.09.021openalex-snapshot
Étude de cohorte prospective des effets de l’infliximab sur le facteur rhumatoïde, les anticorps antipeptides cycliques citrullinés et les anticorps antinucléaires chez les patients ayant une polyarthrite rhumatoïde ancienne
inferred← citeshttps://doi.org/10.1016/j.rhum.2008.12.008openalex-snapshot
Anti-TNFalpha, autoanticorps et maladies auto-immunes
inferred← citeshttps://doi.org/10.1016/j.rhum.2016.11.007openalex-snapshot
Pertinence clinique de la détection précoce des anticorps anti-adalimumab dans la polyarthrite rhumatoïde, la spondylarthrite ankylosante et le rhumatisme psoriasique : étude multicentrique prospective
inferred← citeshttps://doi.org/10.1016/j.sder.2006.08.004openalex-snapshot
Update on Connective Tissue Diseases in Dermatology
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2007.08.003openalex-snapshot
Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents
inferred← citeshttps://doi.org/10.1016/j.semnephrol.2007.02.004openalex-snapshot
Functions of TNF and its Receptors in Renal Disease: Distinct Roles in Inflammatory Tissue Injury and Immune Regulation
inferred← citeshttps://doi.org/10.1016/s0001-7310(07)70159-xopenalex-snapshot
Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera parte: infliximab y adalimumab
inferred← citeshttps://doi.org/10.1016/s0065-2776(06)92001-xopenalex-snapshot
Systemic Lupus Erythematosus: Multiple Immunological Phenotypes in a Complex Genetic Disease
inferred← citeshttps://doi.org/10.1016/s0151-9638(06)77556-1openalex-snapshot
Maladies auto-immunes sous statines
inferred← citeshttps://doi.org/10.1016/s0151-9638(12)70112-6openalex-snapshot
Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis
inferred← citeshttps://doi.org/10.1016/s1297-319x(11)70001-xopenalex-snapshot
TNF alpha antagonist therapy and safety monitoring
inferred← citeshttps://doi.org/10.1016/s1571-5078(05)05022-1openalex-snapshot
Skin Targets for New Biological Agents in Systemic Autoimmune Diseases
inferred← citeshttps://doi.org/10.1016/s1578-2190(07)70539-5openalex-snapshot
Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 1: Infliximab and Adalimumab
inferred← citeshttps://doi.org/10.1016/s1699-258x(07)73679-3openalex-snapshot
Resonancia magnética de la mano en la artritis reumatoide. Revisión de la metodología y la utilidad en el diagnóstico, el seguimiento y el pronóstico
inferred← citeshttps://doi.org/10.1016/s2173-5743(07)70227-7openalex-snapshot
Magnetic Resonance of the Hand in Rheumatoid Arthritis. Review of Methodology and its Use in Diagnosis, Monitoring, and Prognosis
inferred← citeshttps://doi.org/10.1016/s2255-5021(13)70049-xopenalex-snapshot
Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1017/s1462399405009488openalex-snapshot
Molecular therapeutic targets in rheumatoid arthritis
inferred← citeshttps://doi.org/10.1038/ncprheum0708openalex-snapshot
Drug Insight: autoimmune effects of medications—what's new?
inferred← citeshttps://doi.org/10.1038/s41598-024-65378-6openalex-snapshot
Prevalence of antiphospholipid autoantibodies associated with biologics treatment for psoriasis
inferred← citeshttps://doi.org/10.1038/s41598-025-90566-3openalex-snapshot
Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database
inferred← citeshttps://doi.org/10.1080/00325481.2017.1249266openalex-snapshot
TNF-alpha antagonist induced lupus on three different agents
inferred← citeshttps://doi.org/10.1080/03009740701281293openalex-snapshot
Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma
inferred← citeshttps://doi.org/10.1080/09546634.2022.2089331openalex-snapshot
Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review
inferred← citeshttps://doi.org/10.1080/14712598.2017.1346078openalex-snapshot
Safety profile of biological therapies for treating rheumatoid arthritis
inferred← citeshttps://doi.org/10.1080/14712598.2021.1853096openalex-snapshot
The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?
inferred← citeshttps://doi.org/10.1080/1547691x.2026.2622342openalex-snapshot
Evaluating miRNAs as predictive biomarkers for drug-induced autoimmune toxicity in D-penicillamine induced autoimmune diseases animal model
inferred← citeshttps://doi.org/10.1080/17425255.2020.1810233openalex-snapshot
Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa
inferred← citeshttps://doi.org/10.1093/hmg/ddx407openalex-snapshot
De novo mutations implicate novel genes in systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1093/rheumatology/kei227openalex-snapshot
Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis
inferred← citeshttps://doi.org/10.1093/rheumatology/ken089openalex-snapshot
Increased IL-4+ CD8+ T cells in peripheral blood and autoreactive CD8+ T cell lines of patients with inflammatory arthritis
inferred← citeshttps://doi.org/10.1097/01.bor.0000198007.73320.6eopenalex-snapshot
Musculoskeletal manifestations and autoimmune diseases related to new biologic agents
inferred← citeshttps://doi.org/10.1097/mcg.0b013e3181a745e7openalex-snapshot
Adalimumab-induced Autoimmune Hepatitis
inferred← citeshttps://doi.org/10.1097/md.0b013e3181441a68openalex-snapshot
Autoimmune Diseases Induced by TNF-Targeted Therapies
inferred← citeshttps://doi.org/10.1097/mpg.0b013e3181837289openalex-snapshot
Drug‐induced Lupus Associated With Infliximab and Adalimumab in an Adolescent With Crohn Disease
inferred← citeshttps://doi.org/10.1101/2020.06.13.20130039openalex-snapshot
Neutrophil nuclear patterns to distinguish between pathological and non-pathological autoantibodies detected on HEp-2 cells
inferred← citeshttps://doi.org/10.1111/1756-185x.70663openalex-snapshot
Drug‐Induced Subacute Cutaneous Lupus Erythematosus Under Adalimumab in a Child With Polyarticular Juvenile Idiopathic Arthritis: IFN ‐α and TNF ‐α‐Skewed Cytokine Profile
inferred← citeshttps://doi.org/10.1111/apt.12491openalex-snapshot
Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
inferred← citeshttps://doi.org/10.1111/bjd.15866openalex-snapshot
Tumour necrosis factor antagonist-induced lupus: a Critically Appraised Topic
inferred← citeshttps://doi.org/10.1111/cei.12114openalex-snapshot
The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses
inferred← citeshttps://doi.org/10.1111/dth.14826openalex-snapshot
Real‐world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center
inferred← citeshttps://doi.org/10.1111/j.1365-2133.2006.07639.xopenalex-snapshot
A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity
inferred← citeshttps://doi.org/10.1111/j.1365-2133.2009.09563.xopenalex-snapshot
Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis: a retrospective, observational study
inferred← citeshttps://doi.org/10.1111/j.1365-2990.2007.00798.xopenalex-snapshot
Role of tumour necrosis factor α, but not of cyclo‐oxygenase‐2‐derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach
inferred← citeshttps://doi.org/10.1111/j.1365-4632.2011.04871.xopenalex-snapshot
TNF alpha antagonist‐induced lupus‐like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists
inferred← citeshttps://doi.org/10.1111/j.1468-3083.2009.03386.xopenalex-snapshot
Autoimmunity by anti‐tumour necrosis factor‐alpha agents: the role of traditional therapies
inferred← citeshttps://doi.org/10.1111/j.1529-8019.2012.01538.xopenalex-snapshot
Etanercept-induced Wegener granulomatosis in a patient with rheumatoid arthritis
inferred← citeshttps://doi.org/10.1111/j.1600-0463.2010.02677.xopenalex-snapshot
T‐cell expression of CD91 – a marker of unresponsiveness to anti‐TNF therapy in rheumatoid arthritis
inferred← citeshttps://doi.org/10.1111/j.1610-0387.2012.08000.xopenalex-snapshot
Drug‐induced lupus erythematosus with emphasis on skin manifestations and the role of anti‐TNFα agents
inferred← citeshttps://doi.org/10.1111/jcpt.12506openalex-snapshot
A case of lupus-like syndrome in a patient receiving adalimumab and a brief review of the literature on drug-induced lupus erythematosus
inferred← citeshttps://doi.org/10.1111/pde.12576openalex-snapshot
Adalimumab‐Induced Cutaneous Lupus Erythematosus in a 16‐Year‐Old Girl with Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1136/annrheumdis-2013-203485openalex-snapshot
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
inferred← citeshttps://doi.org/10.1136/annrheumdis-2014-205318openalex-snapshot
What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort
inferred← citeshttps://doi.org/10.1136/ard.2004.030262openalex-snapshot
Blockade of tumour necrosis factor α significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis
inferred← citeshttps://doi.org/10.1136/ard.2004.033662openalex-snapshot
Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice
inferred← citeshttps://doi.org/10.1136/ard.2005.042416openalex-snapshot
Current state of tumour necrosis factor α blockade in Wegener's granulomatosis
inferred← citeshttps://doi.org/10.1136/ard.2005.044941openalex-snapshot
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
inferred← citeshttps://doi.org/10.1136/ard.2006.061937openalex-snapshot
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006
inferred← citeshttps://doi.org/10.1136/ard.2006.065052openalex-snapshot
Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset
inferred← citeshttps://doi.org/10.1136/ard.2007.081430openalex-snapshot
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
inferred← citeshttps://doi.org/10.1136/ard.2007.087106openalex-snapshot
Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
inferred← citeshttps://doi.org/10.1136/ard.2008.103291openalex-snapshot
Nucleosome accumulation and reduction of C-reactive protein are associated with the generation of anti-nuclear antibodies in patients with rheumatoid arthritis treated with adalimumab, but not with etanercept
inferred← citeshttps://doi.org/10.1136/ard.2010.146852openalex-snapshot
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
inferred← citeshttps://doi.org/10.1136/bmj.b508openalex-snapshot
Life threatening liver disease during treatment with monoclonal antibodies
inferred← citeshttps://doi.org/10.1136/rmdopen-2017-000555openalex-snapshot
Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients
inferred← citeshttps://doi.org/10.1155/2013/697525openalex-snapshot
Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1155/2014/801072openalex-snapshot
Possible Association of Etanercept, Venous Thrombosis, and Induction of Antiphospholipid Syndrome
inferred← citeshttps://doi.org/10.1155/2021/9989729openalex-snapshot
Antitumor Necrosis Factor‐Alpha (TNF‐ α ) Infliximab‐Induced Pleural Effusion and Pericarditis in Crohn’s Disease
inferred← citeshttps://doi.org/10.1155/crrh/6133434openalex-snapshot
Overlap Myositis in a Patient With Psoriasis Treated With Anti–TNF‐Alpha Therapy: A Case Report and Review of Literature
inferred← citeshttps://doi.org/10.1159/000200022openalex-snapshot
Infliximab Reduces Myeloperoxidase Concentration in Chronic Inflammatory Joint Diseases
inferred← citeshttps://doi.org/10.1159/000289205openalex-snapshot
The First Decade of Biologic TNF Antagonists in Clinical Practice: Lessons Learned, Unresolved Issues and Future Directions
inferred← citeshttps://doi.org/10.1159/000343609openalex-snapshot
Prevalence and Management of Panic Attacks during Infliximab Infusion in Psoriatic Patients
inferred← citeshttps://doi.org/10.1159/000381592openalex-snapshot
Serum Reaction, Lupus-Like Syndrome
inferred← citeshttps://doi.org/10.1177/0961203306071703openalex-snapshot
Lessons for lupus from tumour necrosis factor blockade
inferred← citeshttps://doi.org/10.1177/0961203308098190openalex-snapshot
TNF inhibition in SLE: where do we stand?
inferred← citeshttps://doi.org/10.1177/0961203313479423openalex-snapshot
Infliximab-induced discoid lupus erythematosus
inferred← citeshttps://doi.org/10.1177/0961203317709344openalex-snapshot
The impact of biological treatments on the anti-dsDNA and anti-nucleosome tests
inferred← citeshttps://doi.org/10.1177/247553031218a00305openalex-snapshot
Etanercept-Induced Lupus Panniculitis with Continued Improvement after Treatment with Adalimumab for Psoriatic Arthritis
inferred← citeshttps://doi.org/10.1186/1755-7682-5-7openalex-snapshot
Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α
inferred← citeshttps://doi.org/10.1186/ar1851openalex-snapshot
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study
inferred← citeshttps://doi.org/10.1186/ar2020openalex-snapshot
Predictors of infusion reactions during infliximab treatment in patients with arthritis
inferred← citeshttps://doi.org/10.1186/ar2341openalex-snapshot
The role of tumor necrosis factor-alpha in systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1186/ar3546openalex-snapshot
Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study
inferred← citeshttps://doi.org/10.1186/s12891-020-03609-3openalex-snapshot
Repository corticotropin injection attenuates collagen-induced arthritic joint structural damage and has enhanced effects in combination with etanercept
inferred← citeshttps://doi.org/10.1186/s12969-026-01236-1openalex-snapshot
Tumor necrosis factor inhibitor-related autoimmune disorders in pediatric rheumatology practice: a multicenter nationwide study
inferred← citeshttps://doi.org/10.1191/0961203305lu2240rropenalex-snapshot
The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications
inferred← citeshttps://doi.org/10.1196/annals.1361.115openalex-snapshot
Tumor Necrosis Factor Inhibitor Therapy for Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1196/annals.1398.034openalex-snapshot
Predictive Value of Antibodies to Citrullinated Peptides and Rheumatoid Factors in Anti‐TNF‐α Treated Patients
inferred← citeshttps://doi.org/10.1196/annals.1423.034openalex-snapshot
Autoantibody Production in Anti‐TNF‐α‐Treated Patients
inferred← citeshttps://doi.org/10.14218/jcth.2018.00039openalex-snapshot
Role of Biologics in the Development of Autoimmune Hepatitis: A Review
inferred← citeshttps://doi.org/10.14309/crj.2017.1openalex-snapshot
Cardiac Tamponade as a Presenting Manifestation of Infliximab-Induced Lupus in Patient Treated for Crohn's Disease
inferred← citeshttps://doi.org/10.14412/1995-4484-2017-446-448openalex-snapshot
INFLIXIMAB-INDUCED LUPUS-LIKE SYNDROME IN A FEMALE PATIENT WITH RHEUMATOID ARTHRITIS (A CASE REPORT): AN ACCIDENT OR REGULARITY?
inferred← citeshttps://doi.org/10.1517/14656566.6.1.27openalex-snapshot
Management of hepatitis C virus-related arthritis
inferred← citeshttps://doi.org/10.1517/14712598.6.12.1349openalex-snapshot
Adalimumab for rheumatoid arthritis
inferred← citeshttps://doi.org/10.1517/14740338.7.4.411openalex-snapshot
Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1542/peds.2020-0123openalex-snapshot
Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child
inferred← citeshttps://doi.org/10.15537/1658-3175.5075openalex-snapshot
Medical conditions associated with a positive anti-double-stranded deoxyribonucleic acid.
inferred← citeshttps://doi.org/10.1586/14737167.6.1.25openalex-snapshot
Economic burden of rheumatoid arthritis in France
inferred← citeshttps://doi.org/10.1586/1744666x.2.2.189openalex-snapshot
Current Concepts in Rheumatology, Royal Society of Medicine
inferred← citeshttps://doi.org/10.1586/1744666x.3.4.613openalex-snapshot
The use of laboratory methods in differential diagnosis and treatment of SLE and antiphospholipid syndrome
inferred← citeshttps://doi.org/10.1590/s0482-50042010000600011openalex-snapshot
Uso do infliximabe e aparecimento sequencial de autoanticorpos e neoplasia em paciente com espondiloartrite
inferred← citeshttps://doi.org/10.1590/s0482-50042013000400008openalex-snapshot
Revisão sistemática da indução de autoanticorpos e lúpus eritematoso pelo infliximabe
inferred← citeshttps://doi.org/10.2146/ajhp060365openalex-snapshot
Use of biologics in rheumatoid arthritis: Where are we going?
inferred← citeshttps://doi.org/10.2147/ccid.s4560openalex-snapshot
Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
inferred← citeshttps://doi.org/10.2147/oarrr.s4536openalex-snapshot
Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
inferred← citeshttps://doi.org/10.2165/00003495-200868060-00003openalex-snapshot
Novel Therapies for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
inferred← citeshttps://doi.org/10.2165/11588500-000000000-00000openalex-snapshot
Drug-Induced Lupus Erythematosus
inferred← citeshttps://doi.org/10.2169/internalmedicine.2551-23openalex-snapshot
New-onset Immune-mediated Necrotizing Myopathy and Trigeminal Neuropathy after SARS-CoV-2 mRNA Vaccination in a Patient with Rheumatoid Arthritis and Sjögren's Syndrome
inferred← citeshttps://doi.org/10.2169/internalmedicine.7166-21openalex-snapshot
Cardiac Tamponade During Tocilizumab Therapy in a Patient with Rheumatoid Arthritis and Anti-DNA Antibody Positivity
inferred← citeshttps://doi.org/10.2174/1573397117666211102094330openalex-snapshot
TNF-induced Lupus. A Case-Based Review
inferred← citeshttps://doi.org/10.2174/1874312900802010053openalex-snapshot
The Changing Face of Spondyloarthropathies Under TNF α Blockade
inferred← citeshttps://doi.org/10.2174/1874312901206010315openalex-snapshot
Anti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus§
inferred← citeshttps://doi.org/10.2310/7750.2006.00071openalex-snapshot
Long-Term Safety of Etanercept
inferred← citeshttps://doi.org/10.29328/journal.acgh.1001021openalex-snapshot
Biomarkers in Enteropathic Arthritis
inferred← citeshttps://doi.org/10.3109/03009740902832753openalex-snapshot
Anti-TNF-alpha-induced anti-phospholipid syndrome manifested as necrotizing vasculitis
inferred← citeshttps://doi.org/10.3109/08916934.2013.873414openalex-snapshot
Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy
inferred← citeshttps://doi.org/10.3109/14397595.2016.1153567openalex-snapshot
Association of anti-Ro/SSA antibody with response to biologics in patients with rheumatoid arthritis
inferred← citeshttps://doi.org/10.31138/mjr.32.2.96openalex-snapshot
Biologic Therapies and Autoimmune Phenomena
inferred← citeshttps://doi.org/10.3346/jkms.2006.21.5.946openalex-snapshot
Etanercept-Induced Systemic Lupus Erythematosus in a Patient with Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.3390/ijms19082199openalex-snapshot
Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver
inferred← citeshttps://doi.org/10.3390/ijms22062954openalex-snapshot
Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges
showing the first 200 of 216 · page through all 216
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.